Junker K
Zentrum für Pathologie, Klinikum Bremen-Mitte, St.-Jürgen-Str. 1, 28177, Bremen, Deutschland,
Pathologe. 2014 Nov;35(6):574-7. doi: 10.1007/s00292-014-1919-x.
After neoadjuvant therapy of non-small cell lung cancer, the extent of therapy-induced tumor regression in corresponding resection specimens of primary tumors and lymph nodes represents an independent prognostic factor. In the former tumor area, different sized target-like foci with central necrosis, adjoining narrow foam cell rim, peripheral vascular granulation tissue and transition into a marked scarry fibrosis can be found after neoadjuvant therapy. Morphological changes indicating therapy-induced tumor regression can be graded according to the Bochum regression grading system. Therapy-induced cytomorphological changes do not allow reliable conclusions on the success of the applied neoadjuvant therapy and should not form the basis of cytopathological grading.
非小细胞肺癌新辅助治疗后,原发肿瘤及淋巴结相应切除标本中治疗诱导的肿瘤退缩程度是一个独立的预后因素。在前肿瘤区域,新辅助治疗后可发现不同大小的靶样病灶,中央有坏死,周边有狭窄的泡沫细胞带,外周有血管肉芽组织,并过渡为明显的瘢痕纤维化。可根据波鸿退缩分级系统对提示治疗诱导肿瘤退缩的形态学变化进行分级。治疗诱导的细胞形态学变化无法对所应用新辅助治疗的成功与否得出可靠结论,不应作为细胞病理学分级的依据。